Ontology highlight
ABSTRACT:
SUBMITTER: Walter HS
PROVIDER: S-EPMC4731845 | biostudies-literature | 2016 Jan
REPOSITORIES: biostudies-literature
Walter Harriet S HS Rule Simon A SA Dyer Martin J S MJ Karlin Lionel L Jones Ceri C Cazin Bruno B Quittet Philippe P Shah Nimish N Hutchinson Claire V CV Honda Hideyuki H Duffy Kevin K Birkett Joseph J Jamieson Virginia V Courtenay-Luck Nigel N Yoshizawa Toshio T Sharpe John J Ohno Tomoya T Abe Shinichiro S Nishimura Akihisa A Cartron Guillaume G Morschhauser Franck F Fegan Christopher C Salles Gilles G
Blood 20151105 4
We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies. There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens of 240 mg and 300 mg. Twenty-four of 25 evaluable chronic lymphocytic leukemia (CLL) patients (96%) responded to ONO/GS-4059, with a median treatment duration of 80 weeks; 21 CLL patients remain on t ...[more]